Navigation Links
Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
Date:5/31/2009

atient with ovarian cancer that has returned at least 6 months after the patient had finished platinum-based therapy.

GEMZAR is indicated as a single agent (given alone) as the first-line treatment for patients with locally advanced (Stage II or Stage III when surgery is not an option) or metastatic (Stage IV) adenocarcinoma of the pancreas. GEMZAR is also indicated for patients previously treated with 5-FU (another type of chemotherapy).

GEMZAR in combination with paclitaxel is approved by the FDA for the first-line treatment of patients with metastatic breast cancer after they have received another type of chemotherapy called an anthracycline, unless their medical condition did not allow them to receive an anthracycline.

GEMZAR may not be appropriate for some patients.

If you are allergic to GEMZAR, tell your doctor you should not receive it. GEMZAR can suppress bone marrow function. There have been rare reports of serious kidney or liver toxicity with GEMZAR treatment, sometimes fatal. Serious lung toxicity has also been reported, sometimes fatal. If you think you are pregnant, are planning to become pregnant, or are nursing, please tell your healthcare team. GEMZAR may harm your unborn or nursing baby.

If you have had prior kidney or liver problems or impairment, please tell your healthcare professional. GEMZAR may not be right for you. GEMZAR has not been shown to work in children. Tell your doctor if you are taking other medicines, including prescription and non-prescription medicines, vitamins, or herbal supplements.

There is a risk of side effects associated with GEMZAR therapy. The most common side effects are low blood cell counts (red blood cells, white blood cells, and platelets); fever; infection; hair loss; tiredness; nausea, vomiting, constipation, and diarrhea; rash; shortness of breath; muscle aches; and numbness or tingling in your toes or fingers.
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... WASHINGTON , Jan. 23, 2015  A new analysis ... Part D 2015 enrollment data shows that 81 percent ... convenient access and extra discounts at certain pharmacies. The ... "Preferred pharmacy plans are now the foundation of ...
(Date:1/23/2015)... 23, 2015  MedScope ( www.medscope.org ), the leading provider ... 2015 Connected World magazine Connected World Award ... that can be used anywhere, anytime. The nomination was ... In nominating MedScope, Landon Garner , Director ...
(Date:1/23/2015)... ORLANDO, Fla. and DUBLIN , ... of the agreement with KRS Global Biotechnology, Inc. for the ... will be compounded for shipment in the United ... 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ) announced ... has officially accepted the New Drug Application (NDA),for ... schizophrenia. Acceptance of the NDA confirms that the,application ... Schizophrenia, Schizophrenia is a chronic, severe and ...
... a.m. (EST), A World AIDS Day Call for Changes ... Women,s, Faith-based and Youth Rights,Organizations Call on Congress to Start ... WASHINGTON, Nov. 26 The following was,released by the Center ... 2007, at 10:00 a.m. EST, Who: ...
Cached Medicine Technology:Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application 2Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application 3World AIDS Day Audio Press Conference 2
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... for bowel cancer at Queen,s University Belfast has received ... Dr Sandra Van Schaeybroeck, whose research aims to identify ... a prestigious 688,000 Cancer Research UK Clinical Scientist Fellowship. ... four fellowships awarded to UK clinical investigators, renews Dr ...
... ,Surgeons aged 35 to 50 provide the safest care for ... about ongoing training and motivation of surgeons during their careers, ... France. They analyzed data from 3,574 thyroidectomies (removal of ... over a one-year period. The average age of the surgeons ...
... , TUESDAY, Jan. 10 (HealthDay News) -- Children with autism ... bacteria seen in kids who do not have the disorder, ... 10 in the online journal mBio , researchers from ... New York City suggested that this finding could help explain ...
... patients improved between 2003 and 2008, according to a ... Outcomes , an American Heart Association journal. The study ... of care, and that differences in care between the ... because little is known about the treatment and outcomes ...
... By Serena Gordon HealthDay Reporter , TUESDAY, Jan. ... new research suggests those costs may extend far beyond the ... study authors found that young people with diabetes were more ... lifetime, could expect to earn about $160,000 less than those ...
... that older Americans with cirrhosis have significantly worse health ... this potentially deadly disease. In fact, findings now published ... American Association for the Study of Liver Diseases, show ... of informal caregiving and contribute added strain on the ...
Cached Medicine News:Health News:Groundbreaking cancer research receives massive funding boost 2Health News:Surgeons in Mid-Career Have Fewest Complications: Study 2Health News:Autism Gastro Problems May Be Linked to Gut Bacteria 2Health News:Asian-Americans getting better heart attack care 2Health News:Diabetes Takes a Toll on Lifetime Earnings: Study 2Health News:Diabetes Takes a Toll on Lifetime Earnings: Study 3Health News:Diabetes Takes a Toll on Lifetime Earnings: Study 4Health News:High rates of disability and health care use for older americans with cirrhosis 2
ACE Control Serum provides the laboratory with vital information on the performance of the ACE chemistry assay....
Medical Claims Billing...
e-MDs Bill practice management system is used in the medical billing cycle....
BillingPro...
Medicine Products: